Results 171 to 180 of about 33,638 (296)
British Journal of Haematology, Volume 206, Issue 4, Page 1246-1249, April 2025.In this study, we collected real‐world evidence on the use of pegcetacoplan among 22 Italian patients with paroxysmal nocturnal haemoglobinuria showing suboptimal response to anti‐C5 treatments eculizumab and ravulizumab. Most patients exhibited a complete or good response as per the criteria of the European Bone Marrow Transplant group (Risitano et al.
Elisabetta Metafuni +19 more
wiley +1 more source
An uncommon association: Sjogren's syndrome and autoimmune myelofibrosis [PDF]
, 1999 Isabelle Marié
openalex +1 more source
Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review
British Journal of Pharmacology, Volume 182, Issue 7, Page 1416-1445, April 2025.Abstract In the past year, the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) authorised 53 novel drugs. While the 2024 harvest is not as rich as in 2023, when 70 new chemical entities were approved, the number of ‘orphan’ drug authorisations in 2024 (21) is ...
Stavros Topouzis +16 more
wiley +1 more source
International Journal of Laboratory Hematology, Volume 47, Issue 2, Page 236-245, April 2025.ABSTRACT Introduction The first‐step in diagnosis of myelodysplastic neoplasms (MDS) is essentially based on bone marrow cytomorphology. However, cytomorphology of MDS is often a difficult exercise, subject to inter‐operator variability. Our study aims to evaluate whether the combination of two dysplasia scores, the extended Ogata score and the MDS‐CBC
Ludovic Firrera +6 more
wiley +1 more source
Immune thrombocytopenia in postpolythemic myelofibrosis [PDF]
, 1997 Zwi A. Schreiber
openalex +1 more source
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial [PDF]
, 2017 DiPersio, John F, et al,
core +1 more source
Journal of Sleep Research, Volume 34, Issue 2, April 2025.Summary Little is known about the correlation between subjective perception and objective measures of sleep quality in particular in the oldest‐old. The aim of this study was to perform longitudinal home sleep monitoring in this age group, and to correlate results with self‐reported sleep quality.
Hugo Saner +4 more
wiley +1 more source
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome [PDF]
, 2023 Cilloni, Daniela
core +1 more source
Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis
Liver International, Volume 45, Issue 4, April 2025.ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) is caused by metabolic triggers and genetic predisposition. Among the genetic MASLD risk variants identified today, the common PNPLA3 148M variant exerts the largest effect size of MASLD heritability.
Daniel Lindén +2 more
wiley +1 more source